AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11514481
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for primary prevention at CHD risk 15% over 10 years
Trial: 11514481
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for primary prevention at CHD risk 6% over 10 years
Trial: 11514481
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment at projected CHD risk 20% over 10 years
Trial: 30873671
Drug: Black seed
RxNorm normalized name: BLACK SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black seed capsules (500 mg) two times per day for 10 weeks
Trial: 27378000
Drug: Preoperative dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative dexketoprofen trometamol (25 mg 30 min before surgery)
Trial: 27378000
Drug: Postoperative dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative dexketoprofen trometamol (25 mg immediately after surgery)
Trial: 20199786
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Simvastatin + Ezetimibe)
Trial: 15889952
Drug: Oral quetiapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quetiapine (493 mg/day at week 48)
Trial: 15889952
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol decanoate (170 mg/28 days at week 48)
Trial: 8671571
Drug: High titre
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titre measles vaccine
Trial: 8671571
Drug: Medium titre
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium titre measles vaccine
Trial: 8671571
Drug: High titre
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titre measles vaccine (females)
Trial: 8671571
Drug: High titre
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titre measles vaccine (males)
Trial: 8671571
Drug: Standard titre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard titre measles vaccine
Trial: 1931060
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium (1.0 mg/kg to 4 mg/kg)
Trial: 6210665
Drug: mezlocillin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin (1.5 g) administered intramuscularly every 6 hr for seven to ten days
Trial: 6210665
Drug: ticarcillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticarcillin (2 g) administered intramuscularly every 6 hr for seven to ten days
Trial: 30672213
Drug: Climen tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climen tablet prescribed orally from the 5th day of menstruation, one tablet a time, once a day for 3 months (7 days between two 21-day medication).
Trial: 20667889
Drug: posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: posaconazole 400 mg twice daily
Trial: 20667889
Drug: fosamprenavir/ritonavir 700/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosamprenavir/ritonavir 700/100 mg twice daily
Trial: 20667889
Drug: posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: posaconazole 400 mg twice daily with fosamprenavir 700 mg twice daily
Trial: 11973215
Drug: Bupivacaine 0.0625%
RxNorm normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.0625% plus fentanyl 2 microg/mL
Trial: 11973215
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% plus fentanyl 2 microg/mL
Trial: 9454395
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of penicillin
Trial: 9454395
Drug: Penicillin tablets
RxNorm normalized name: Penicillin V
DrugBank: Meticillin (DB01603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin tablets for six days
Trial: 8585875
Drug: Pravastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin therapy at a dose of 20 mg/die
Trial: 8585875
Drug: Dietetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietetic treatment and placebo after pravastatin suspension
Trial: 23313720
Drug: Attention and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention and dose‐matched control program (n = 52)
Trial: 10668412
Drug: CP-101,606 (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-101,606 (0.75 mg/kg/hr for 2 hours, then 0.37 mg/kg/hr for 22 or 70 hours)
Trial: 2110537
Drug: Morniflumate suppositories
RxNorm normalized name: morniflumate
DrugBank: Morniflumate (DB09285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morniflumate suppositories (400 mg, twice daily for 4 days)
Trial: 2110537
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 4 days)
Trial: 31115111
Drug: Episodic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic treatment for bleeding
Trial: 19996674
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group implants placed 2 mm supracrestally
Trial: 19996674
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group implants positioned at bone level
Trial: 15145175
Drug: Proton-photon radiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-photon radiotherapy, mean prescribed dose 76.3 CGE
Trial: 11773293
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy for 1-3 years
Trial: 11773293
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy for 5 years
Trial: 11773293
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy for longer than 5 years
Trial: 2888017
Drug: Glucocorticoid (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (30 mg/kg bolus followed by 5 mg/kg/hour infusion for 9 hours)
Trial: 2196240
Drug: TBF +
RxNorm normalized name: Trifluridine plus tipiracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBF + R administered in 3 office visits over 8 weeks
Trial: 2196240
Drug: TBF +
RxNorm normalized name: Trifluridine plus tipiracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBF + R plus instruction in cognitive stress coping techniques administered in 5 office visits over 8 weeks
Trial: 26206666
Drug: Nebulized racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized racemic salbutamol solution
Trial: 26206666
Drug: 3% sodium
RxNorm normalized name: Dextrose 5% and 0.3% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% sodium chloride (NaCl) solution
Trial: 21788033
Drug: Leuprolide to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide to Degarelix (240/80 mg or 240/160 mg)
Trial: 15452182
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (doxorubicin-based)
Trial: 12410926
Drug: Butylscopolamine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butylscopolamine (intravenous injection)
Trial: 9661636
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose load before surgery
Trial: 9661636
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral glucose load before surgery
Trial: 9661636
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during post-op clamp
Trial: 2651174
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release indomethacin 75 mg/day
Trial: 333568
Drug: Sydnocarb (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sydnocarb (5-15 mg)
Trial: 23357210
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Doxazosin + Finasteride)
Trial: 22289552
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose antibiotic (n = 37)
Trial: 22289552
Drug: Single-dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antibiotic (n = 31)
Trial: 9673754
Drug: BIP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIP chemotherapy followed by radiotherapy (RT) in CT-RT Group
Trial: 9673754
Drug: BIP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIP chemotherapy followed by RT in CT-RT Group (study 2)
Trial: 8082875
Drug: Alprazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.5 mg orally)
Trial: 2567266
Drug: Olsalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (2 g/day)
Trial: 2567266
Drug: Sulphasalazine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (3 g/day)
Trial: 31023432
Drug: Dietary fish-oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fish-oil supplementation of 2.5 g/day
Trial: 17785037
Drug: E2V (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2V (1 mg) + MPA (2.5 mg)
Trial: 17785037
Drug: E2V (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2V (2 mg) + MPA (5 mg)
Trial: 17785037
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (E2V and MPA combinations)
Trial: 15097809
Drug: Iodinated oral
RxNorm normalized name: iodine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodinated oral contrast (IOC)
Trial: 7988628
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice daily for 3 days)
Trial: 31930518
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST) based on Roy's adaptation model
Trial: 23991658
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg once daily or 30 mg once daily for specific patients)
Trial: 23991658
Drug: Warfarin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (in patients with pulmonary embolism and right ventricular dysfunction)
Trial: 21911723
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg daily
Trial: 21911723
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus octreotide (TAM-OCT) 90 mg depot monthly for 2 years
Trial: 17900778
Drug: Treatment-resistant schizophrenia
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-resistant schizophrenia patients
Trial: 17900778
Drug: Treatment-responsive chronic
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-responsive chronic schizophrenia patients
Trial: 10791645
Drug: Bioabsorbable poly‐L‐lactide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable poly‐L‐lactide lag screws (3 screws of 6.3 mm diameter)
Trial: 10791645
Drug: Bioabsorbable poly‐L‐lactide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable poly‐L‐lactide lag screws
Trial: 3730021
Drug: Flupenthixol (Fluanxol)
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol (Fluanxol) 0.5 mg, 1 mg, and 2 mg/day
Trial: 28970207
Drug: Hydroxychloroquine 400 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg/day and sulfasalazine 2000 mg/day (arm 1)
Trial: 28970207
Drug: Methotrexate plus
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate plus adalimumab 40 mg/2 weeks (arm 2)
Trial: 24767603
Drug: Low-intensity online
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity online CBT-based treatment consisting of six weekly modules; participants receive weekly post-session feedback.
Trial: 20339354
Drug: Hourly mean
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly mean method
Trial: 18823460
Drug: Pre-operative i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative i.v. fluid loading with a balanced crystalloid solution (1 ml/kg/h over 48 h)
Trial: 27256706
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose hUCB-MSCs (5.0 × 10^7)
Trial: 27256706
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hUCB-MSCs (2.5 × 10^7)
Trial: 23179858
Drug: Glibenclamide (Gb)
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide (Gb) 3.5 mg, intravenously or orally
Trial: 23179858
Drug: Metabolite M1
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metabolite M1 3.5 mg, intravenously
Trial: 23179858
Drug: Metabolite M2
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metabolite M2 3.5 mg, intravenously
Trial: 21654053
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/d for six months
Trial: 21654053
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lower doses of statins)
Trial: 19505424
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine L-aspartate (LOLA) infusion (30 g daily for 3 days)
Trial: 23724353
Drug: Duloxetine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (any dose)
Trial: 8486876
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml 20% Lipofundin MCT/LCT (1/1) per day
Trial: 8486876
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml 20% Lipofundin S (LCT) infused over 8 h each evening
Trial: 3497041
Drug: Troleandomycin 2
RxNorm normalized name: troleandomycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troleandomycin 2 g/day p.o. for 7 days
Trial: 19884374
Drug: Nemonoxacin (TG-873870)
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (TG-873870) 75 to 1,000 mg once daily for 10 days
Trial: 19884374
Drug: Nemonoxacin (TG-873870)
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (TG-873870) 500 mg cohort
Trial: 16870075
Drug: P‐ERMS (KADIAN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐ERMS (KADIAN) once‐daily (QD) dosing
Trial: 16870075
Drug: CRO (OxyContin)
RxNorm normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CRO (OxyContin) twice‐daily (BID) dosing
Trial: 12965981
Drug: 2.5‐mg dronabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5‐mg dronabinol (delta‐9‐tetrahydrocannabinol) capsule
Trial: 11789210
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (SM) with oxygen inhalation and anti-infection agents (SM 40 ml + 10% glucose 100 ml)
Trial: 11789210
Drug: Aminophylline (AP)
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (AP) with 10% glucose (AP 0.25 g plus 10% glucose 100 ml)
Trial: 8874180
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HDAC) at 2 g/m2 intravenously every 12 hours for 12 doses plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Trial: 8874180
Drug: Standard-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose cytarabine (SDAC) 200 mg/m2/d for 7 days by continuous infusion plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Trial: 1997047
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and Thiopentone (combination)
Trial: 6647201
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of lipophilic beta-blockers
Trial: 29898842
Drug: ARNI prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARNI prescription post-guideline publication
Trial: 29898842
Drug: ARNI prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARNI prescription pre-guideline publication
Trial: 25062420
Drug: Lifestyle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle + Drug
Trial: 19961574
Drug: Sodium ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ibuprofen (2x256 mg tablets)
Trial: 19961574
Drug: Ibuprofen/poloxamer (2x200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/poloxamer (2x200 mg tablets + 60 mg poloxamer 407)
Trial: 19961574
Drug: Standard ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ibuprofen (2x200 mg tablets)
Trial: 9549651
Drug: Felbamate (3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbamate (3,000 or 3,600 mg/day)
Trial: 9549651
Drug: Felbamate (3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbamate (3,000 or 3,600 mg/day) with erythromycin (333 mg three times daily for 10 days)
Trial: 23652752
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate 0.4% ointment
Trial: 23652752
Drug: Lidocaine chlorohydrate
RxNorm normalized name: Aluminum Chlorohydrate
DrugBank: Aluminum chlorohydrate (DB11573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine chlorohydrate 2.5% gel
Trial: 8889855
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium intake (greater than 1000 mg/day) with physical activity
Trial: 8889855
Drug: Mean calcium
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean calcium intake less than 1000 mg/day with physical activity
Trial: 9141257
Drug: Ibuprofen 8
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 8 mg/kg
Trial: 3882308
Drug: Ibuprofen 12
RxNorm normalized name: ibuprofen 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 12 mg/kg
Trial: 3882308
Drug: Ibuprofen 14
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 14 mg/kg
Trial: 3882308
Drug: Ibuprofen (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (all doses except 0 mg/kg)
Trial: 30740297
Drug: Denosumab (DB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (DB group; 120 mg per 4 weeks plus an additional 120 mg on days 8 and 15; n=125)
Trial: 30740297
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA group; 4 mg per 4 weeks; n=125)
Trial: 20236990
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) delivered by trained nurses in three individual appointments
Trial: 19388288
Drug: Antibiotic-impregnated ventricular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated ventricular catheter (Group A)
Trial: 19388288
Drug: Plain ventricular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain ventricular catheters with prophylactic dual antibiotics (Group B)
Trial: 9440384
Drug: Traditional yogurt
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional yogurt (125 g/d for 1 month)
Trial: 9440384
Drug: Milk fermented
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fermented with yogurt cultures and Lactobacillus casei (YC) (125 g/d for 1 month)
Trial: 9440384
Drug: Nonfermented gelled
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonfermented gelled milk (125 g/d for 1 month)